NIH to Prioritize Human-Based Research Technologies, Expanding Opportunities for GATC Health’s AI-driven Analytic Tools

Irvine, CA – May 01, 2025 – GATC Health Corp, an AI-powered clinical intelligence company​, applauds the National Institutes of Health’s (NIH) recently announced major initiative to prioritize human-based research technologies and reduce the use of animals in NIH-funded studies. This move aligns with recent FDA and EPA efforts to encourage alternatives to animal testing and reflects growing recognition of the limitations in translating animal research results to human diseases.

Key components of the initiative include:

• Accelerating the development and adoption of advanced human-relevant research tools such as organoids, tissue chips, computational models, and real-world data analysis. These technologies enable more precise modeling of human diseases, capture patient-specific variability, and simulate human biological systems and drug responses.

• Establishing the Office of Research Innovation, Validation, and Application (ORIVA) to coordinate NIH-wide efforts, validate new approaches, expand funding and training, and serve as a hub for regulatory and interagency collaboration.

• Updating funding criteria to emphasize the suitability, translatability, and human relevance of research methods, and expanding infrastructure to make non-animal approaches more accessible.

• Implementing training for grant reviewers to mitigate bias toward animal studies and including experts in alternative methods in review panels.

• Publicly reporting on research spending to track progress in shifting funding from animal studies to human-based approaches.

“We are witnessing a disruption to the scientific status quo in these government agencies,” remarked Jayson Uffens, Chief Technology Officer at GATC Health. “It is remarkable that the NIH has followed the FDA and EPA in announcing an initiative specifically aimed at replacing animal testing with human-focused tools like GATC’s in silico models. We are perfectly positioned to help the NIH identify which research programs should receive funding using our Multiomics Advanced Technology™ platform’s analytical tools to predict safety, efficacy, and side effects.”  

For GATC Health stakeholders, this NIH initiative directly supports and validates the company’s focus on AI-driven, human-based research platforms. GATC Health’s technology aligns with the NIH’s vision by providing advanced computational models and data-driven tools that can accelerate drug discovery, improve translational success, and reduce reliance on animal testing—positioning the company at the forefront of this industry-wide transformation.

About GATC Health

GATC Health Corp. is a technology company transforming drug discovery and development through its AI-driven platform and approach. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects.

For more information, visit www.gatchealth.com.